Severity of Sarcopenia in Parkinson's Disease

Launched by ANKARA UNIVERSITY · Jun 7, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the severity of sarcopenia, which is the loss of muscle mass and strength, in people with Parkinson's disease. The researchers want to understand how this condition affects patients aged 40 to 75 who have been diagnosed with Parkinson's by a neurologist. They will compare these patients to healthy individuals of similar age and background to see how muscle loss differs between the two groups. To evaluate the severity of Parkinson's disease and muscle health, participants will undergo a series of assessments, including a scale that measures the stages of the disease and ultrasound scans to measure thigh muscle thickness.

To take part in this study, individuals must be diagnosed with Parkinson's disease, fall within stages 1 to 3 of a specific scale, and have a good level of mental function as indicated by a score on a mental examination. Unfortunately, those who have trouble communicating, severe vision problems, additional neurological disorders, or heart failure, as well as those for whom exercise isn’t recommended, will not be eligible. Participants can expect to undergo non-invasive tests and contribute to important research that could help improve the understanding of muscle loss in Parkinson's disease. The study is currently recruiting 80 participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Score between 24 and 30 on the Mini Mental State Examination
• • Be diagnosed with Parkinson's Disease by a neurologist
• • Stage 1-3 on the Modified Hoehn and Yahr Scale
• Exclusion Criteria:
• • Inability to communicate verbally
• • Elderly people with severe visual impairment, neurological disorders in addition to Parkinson's and/or congestive heart failure
• • Older adults in whom exercise is not recommended